How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT

Radiographics

Volumn 31, Issue 5, 2011, Pages 1287-1305

  Maurer, Alan H ^a   Burshteyn, Mark ^a   Adler, Lee P ^a   Steiner, Robert M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FATTY ACID; FLUORINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ARTIFACT; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIET RESTRICTION; DIFFERENTIAL DIAGNOSIS; EATING; HEART MUSCLE; HEART TUMOR; HUMAN; IMAGE PROCESSING; MEDIASTINUM TUMOR; METABOLISM; MUSCLE; SCINTISCANNING; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

ARTIFACTS; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; EATING; FASTING; FATTY ACIDS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HEART NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INSULIN; MEDIASTINAL NEOPLASMS; MUSCLES; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 80052880862     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.315115003     Document Type: Article

References (72)

1. Opie L, Lopaschuk G. Fuels: aerobic and anaerobic metabolism. In: Opie L, ed. Heart physiology: from cell to circulation. Philadelphia, Pa: Lippincott Williams & Wilkins, 2004;306-354.
2. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 1974;36:413-459.
3. Herrero P, Gropler RJ. Imaging of myocardial metabolism. J Nucl Cardiol 2005;12(3):345-358.
4. Abel ED. Glucose transport in the heart. Front Biosci 2004;9:201-215.
5. Choi Y, Brunken RC, Hawkins RA, et al. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans. Eur J Nucl Med 1993;20(4):308-318.
6. Paolisso G, Gambardella A, Galzerano D, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994;43(2):174-179.
7. Taylor M, Wallhaus TR, Degrado TR, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 2001;42(1):55-62.
8. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging 2005;32(1):98-101.
9. Ding HJ, Shiau YC, Wang JJ, Ho ST, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F]fluoro-2-deoxy-d-glucose. Nucl Med Commun 2002;23(10):961-965.
10. Kaneta T, Hakamatsuka T, Takanami K, et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 2006;20(3):203-208.
11. Khandani AH, Isasi CR, Donald Blaufox M. Intra-individual variability of cardiac uptake on serial whole-body 18F-FDG PET. Nucl Med Commun 2005;26(9):787-791.
12. Berry JJ, Baker JA, Pieper KS, Hanson MW, Hoffman JM, Coleman RE. The effect of metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. J Nucl Med 1991;32(8):1518-1525.
13. Gropler RJ, Siegel BA, Lee KJ, et al. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 1990;31(11):1749-1756.
14. Doot RK, Dunnwald LK, Schubert EK, et al. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med 2007;48(6):920-925.
15. Inglese E, Leva L, Matheoud R, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med 2007;48(10):1662-1669.
16. Fukuchi K, Ohta H, Matsumura K, Ishida Y. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies. Br J Radiol 2007;80(949):3-11.
17. Jingu K, Kaneta T, Nemoto K, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys 2006;66(3):845-851.
18. Maurer AH, Burshteyn M, Adler LP, Gaughan JP, Steiner RM. Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease. J Thorac Imaging 2011 Jun 21. [Epub ahead of print]
19. Feygin J, Hu Q, Swingen C, Zhang J. Relationships between regional myocardial wall stress and bioenergetics in hearts with left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2008;294(5): H2313-H2321.
20. Williams G, Kolodny G. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 2008;190(2):W151-W156.
21. Roy FN, Beaulieu S, Boucher L, Bourdeau I, Cohade C. Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med 2009;50(2):178-183.
22. Israel O, Weiler-Sagie M, Rispler S, et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J Nucl Med 2007;48(2):234-239.
23. Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 2008;35(1):95-99.
24. Jameel MN, Zhang J. Myocardial energetics in left ventricular hypertrophy. Curr Cardiol Rev 2009;5(3):243-250.
25. Oikawa M, Kagaya Y, Otani H, et al. Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol 2005;45(11):1849-1855.
26. Fujii H, Ide M, Yasuda S, Takahashi W, Shohtsu A, Kubo A. Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET. Ann Nucl Med 1999;13(1):55-59.
27. Goto K, Okamoto E, Morita M, et al. Cardiac sarcoidosis detected by FDG-PET [in Japanese]. Nippon Naika Gakkai Zasshi 2005;94(7):1396-1398.
28. Loukas M, Tubbs RS, Tongson JM, et al. The clinical anatomy of the crista terminalis, pectinate muscles and the teniae sagittalis. Ann Anat 2008;190(1):81-87.
29. Akcay M, Bilen ES, Bilge M, Durmaz T, Kurt M. Prominent crista terminalis: as an anatomic structure leading to atrial arrhythmias and mimicking right atrial mass. J Am Soc Echocardiogr 2007;20(2):197. e9-197. e10.
30. D'Amato N, Pierfelice O, D'Agostino C. Crista terminalis bridge: a rare variant mimicking right atrial mass. Eur J Echocardiogr 2009;10(3):444-445.
31. Pandit N, Yeung HW. F-18 FDG pericardial uptake secondary to recent cardiac surgery. Clin Nucl Med 2001;26(11):984-985.
32. Goethals I, Dierckx R, De Meerleer G, et al. The role of nuclear medicine in the prediction and detection of radiation-associated normal pulmonary and cardiac damage. J Nucl Med 2003;44(9):1531-1539.
33. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46(6):983-995.
34. Kesner A, Lau V, Speiser M, et al. Time-course of effects of external beam radiation on FDG uptake in healthy tissue and bone marrow [abstr]. J Nucl Med 2007;48(suppl):337P.
35. Posner MR, Cohen GI, Skarin AT. Pericardial disease in patients with cancer: the differentiation of malignant from idiopathic and radiation-induced pericarditis. Am J Med 1981;71(3):407-413.
36. Cosset JM, Henry-Amar M, Girinski T, Malaise E, Dupouy N, Dutreix J. Late toxicity of radiotherapy in Hodgkin's disease: the role of fraction size. Acta Oncol 1988;27(2):123-129.
37. Thurber DL, Edwards JE, Achor RW. Secondary malignant tumors of the pericardium. Circulation 1962;26:228-241.
38. Grebenc ML, Rosado de Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation. RadioGraphics 2000;20(4):1073-1103.
39. Agostini D, Babatasi G, Galateau F, Grollier G, Potier JC, Bouvard G. Detection of cardiac myxoma by F-18 FDG PET. Clin Nucl Med 1999;24(3):159-160.
40. Dorsay TA, Ho VB, Rovira MJ, Armstrong MA, Brissette MD. Primary cardiac lymphoma: CT and MR findings. J Comput Assist Tomogr 1993;17(6):978-981.
41. Buchmann I, Wandt H, Wahl A, Reske SN. FDG PET for imaging pericardial manifestations of Hodgkin lymphoma. Clin Nucl Med 2003;28(9):760-761.
42. Chang CY, Tsai CS, Peng YJ, Huang WS. Large B-cell lymphoma mimicking ischemic heart disease demonstrated by F-18 fluorodeoxyglucose PET/CT in a heart transplant patient. J Nucl Cardiol 2007;14(5):754-757.
43. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. RadioGraphics 2010;30(1):269-291.
44. Weijs LE, Arsos G, Baarslag HJ, Wittebol S, de Klerk JM. Pericardial involvement in a non-Hodgkin lymphoma patient: coregistered FDG-PET and CT imaging. Eur Heart J 2007;28(22):2698.
45. Zingas AP, Carrera JD, Murray CA 3rd, Kling GA. Lipoma of the myocardium. J Comput Assist Tomogr 1983;7(6):1098-1100.
46. Fan C-M, Fischman AJ, Kwek BH, Abbara S, Aquino SL. Lipomatous hypertrophy of the interatrial septum: increased uptake on FDG PET. AJR Am J Roentgenol 2005;184(1):339-342.
47. Heyer CM, Kagel T, Lemburg SP, Bauer TT, Nicolas V. Lipomatous hypertrophy of the interatrial septum: a prospective study of incidence, imaging findings, and clinical symptoms. Chest 2003;124(6):2068-2073.
48. Kuester LB, Fischman AJ, Fan C-M, Halpern EF, Aquino SL. Lipomatous hypertrophy of the interatrial septum: prevalence and features on fusion 18F fluorodeoxyglucose positron emission tomography/CT. Chest 2005;128(6):3888-3893.
49. Kaste SC, Howard SC, McCarville EB, Krasin MJ, Kogos PG, Hudson MM. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol 2005;35(2):141-154.
50. Rao PM, Woodard PK, Patterson GA, Peterson LR. Myocardial metastasis or benign brown fat? Circ Cardiovasc Imaging 2009;2(4):e25-e27.
51. Tatsumi M, Engles JM, Ishimori T, Nicely O, Cohade C, Wahl RL. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 2004;45(7):1189-1193.
52. Weber WA. Brown adipose tissue and nuclear medicine imaging. J Nucl Med 2004;45(7):1101-1103.
53. Liu Y, Ghesani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Semin Nucl Med 2010;40(4):294-315.
54. Zöphel K, Hölzel C, Dawel M, Hölscher T, Evers C, Kotzerke J. PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy. Eur J Nucl Med Mol Imaging 2007;34(8):1322-1323.
55. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005;111(7):887-893.
56. Takano H, Nakagawa K, Ishio N, et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int J Cardiol 2008;130(1):e11-e13.
57. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145(3):234-241.
58. Dannenberg AM Jr. Macrophages in inflammation and infection. N Engl J Med 1975;293(10):489-493.
59. Perry A, Vuitch F. Causes of death in patients with sarcoidosis: a morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119(2):167-172.
60. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58(6):1204-1211.
61. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007;132(6):1949-1953.
62. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45(12):1989-1998.
63. Sussman SK, Halvorsen RA Jr, Silverman PM, Saeed M. Paracardiac adenopathy: CT evaluation. AJR Am J Roentgenol 1987;149(1):29-34.
64. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007;293(2):E444-E452.
65. Rao PM, Woodard PK, Patterson GA, Peterson LR. Myocardial metastasis or benign brown fat? Circ Cardiovasc Imaging 2009;2(4):e25-e27.
66. Yeung HW, Grewal RK, Gonen M, Schöder H, Larson SM. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003;44(11):1789-1796.
67. De Winter F, Vogelaers D, Gemmel F, Dierckx RA. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002;21(4):247-257.
68. Yen RF, Chen YC, Wu YW, Pan MH, Chang SC. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis: a preliminary report. Acad Radiol 2004;11(3):316-321.
69. Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol 2010;17(3):516-519.
70. Mäki M, Luotolahti M, Nuutila P, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 1996;93(9):1658-1666.
71. Vilain D, Bochet J, Le Stanc E, Wattel C, Hameg A, Tainturier C. Unsuspected hibernating myocardium detected by routine oncology (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2010;37(2):409.
72. Zanco P, Desideri A, Mobilia G, et al. Effects of left bundle branch block on myocardial FDG PET in patients without significant coronary artery stenoses. J Nucl Med 2000;41(6):973-977.